Advancing IPF Care: New Evidence and Economic Considerations in Treatment Decision-Making
Panelists discuss how the clinical and economic burden of idiopathic and progressive pulmonary fibrosis (IPF and PPF) underscores the need for earlier diagnosis, improved care coordination, and emerging therapies that may close treatment gaps while balancing efficacy with health care resource utilization.
Episodes
May 28th 2025EP. 1: The IPF Journey: Pathophysiology, Progression, and Patient Impact
Panelists discuss how idiopathic pulmonary fibrosis (IPF), a progressive and often fatal interstitial lung disease, presents significant clinical challenges due to its variable trajectory, limited treatment options, and poor prognosis—underscoring the importance of early diagnosis and specialized care and the need for therapies that can more effectively alter disease progression.
May 28th 2025EP. 2: Decoding Progressive Pulmonary Fibrosis
Panelists discuss how progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF), though distinct in etiology, share a common trajectory of irreversible lung scarring and functional decline—highlighting the importance of recognizing progressive phenotypes across interstitial lung diseases to guide timely diagnosis, personalized treatment, and improved patient outcomes.
